Anna Kaltenboeck

@a_kaltenboeck

Health economist & policy researcher . Drug pricing focus. Views my own. RT≠endorsement.

NY
Vrijeme pridruživanja: rujan 2016.

Tweetovi

Blokirali ste korisnika/cu @a_kaltenboeck

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @a_kaltenboeck

  1. Prikvačeni tweet
    21. sij

    Hi everyone - just published on value-based pricing in with cc 💊 about VBP for drugs follows below💊 1/11

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 9 sati

    The President sent a clear signal to Senate leadership in support of 's bill to stop drug corporation price gouging. Contrary to the President’s claim, Rx prices aren't coming down-they continue to rise. The House did its job w/H.R. 3. Now the Senate must act.

    Poništi
  3. proslijedio/la je Tweet

    I spoke in front of 3,000 Iowa Republicans last night. It was like a MAGA rally. I told them we needed a President who doesn’t lie all the time. The crowd booed me. I told them we needed a President who wasn’t indecent & cruel. The crowd booed me. 1/

    Prikaži ovu nit
    Poništi
  4. RT Trends in access to care from 2011-2017. Super interesting read

    Poništi
  5. proslijedio/la je Tweet
    4. velj

    Opinion: If more people have health insurance, why is health care getting less affordable?

    Poništi
  6. proslijedio/la je Tweet

    I examined how the Top 4 Democratic candidates (current national standings) propose to reduce Prescription Drug Costs. All great ideas. In bold font are the more unique proposals they emphasize.

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    31. sij

    Don't forget: The FDA has long known that many expired medicines remain safe and potent for years longer.

    Poništi
  8. proslijedio/la je Tweet
    31. sij

    Great thread on value-based pricing (, it looks like you took ’s class on tweeting with gifs 👌🏼)

    Poništi
  9. proslijedio/la je Tweet
    31. sij

    “If you know that you can’t get $14,000 for your cancer drug that is garbage...then maybe that would help us get the right type of innovation.” -, dishing out a full month’s supply of common sense on ’s Outspoken Oncology.

    Prikaži ovu nit
    Poništi
  10. 30. sij

    Check out and on relationship b/t policy & returns on innovation. The interactive tool alone is worth it!

    Poništi
  11. proslijedio/la je Tweet
    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    25. sij

    A new analysis finds that patient groups funded by drug makers generally support corporate interests, few groups have policies governing industry backing, and transparency is often lacking.

    Poništi
  13. proslijedio/la je Tweet
    24. sij

    BREAKING: CDC reports second U.S. case of novel virus spreading in China

    Poništi
  14. proslijedio/la je Tweet

    another pricey cancer drug approved on super small trial with surrogate endpoint.

    Poništi
  15. proslijedio/la je Tweet
    23. sij

    We share our strength when we share our stories. Here's mine. Together we can restore balance to ensure we get the innovative new drugs we need at prices we can afford.

    Poništi
  16. 23. sij

    Thought experiment: if we put and excise tax on these expenditures, what would happen, and what could we do with the money?

    Poništi
  17. 23. sij

    Interesting read for anyone interested in COI among industry-funded patient groups. US is not the only country with this concern

    Poništi
  18. proslijedio/la je Tweet
    23. sij

    Some surprises in new report on in Maryland's program : 1. Spreads = $72M (+10.4%) over payments to 2. Net *increase* of 58 small/independent pharmacies (+15%) Both sides in vs. debate can claim some vindication

    Poništi
  19. proslijedio/la je Tweet
    23. sij

    Civica Rx is teaming with the Blue Cross Blue Shield and 18 of its health plans to supply copycat medicines.

    Poništi
  20. proslijedio/la je Tweet
    23. sij
    Poništi
  21. proslijedio/la je Tweet

    Financial Conflict of Interests in Medicine. Following discussion with here is a draft proposal. We don’t want everyone involved in clinical trials to be labeled as conflicted - coz if everyone is conflicted then no one is conflicted. Comments welcome.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·